Modality
ERT
MOA
PCSK9i
Target
TNFα
Pathway
PD-1/PD-L1
HSThymoma
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
→ Aug 2028
Phase 1Current
NCT08608826
1,712 pts·HS
2017-05→2028-08·Terminated
1,712 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-152.4y awayPh2 Data· HS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2028-08-15 · 2.4y away
HS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08608826 | Phase 1/2 | HS | Terminated | 1712 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 |